Current Treatment Options in Oncology最新文献_第10页

Neoadjuvant Photodynamic Therapy: An Updated Therapeutic Approach for Non-Melanoma Skin Cancers. 新辅助光动力疗法：非黑色素瘤皮肤癌的最新治疗方法。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-06-01 Epub Date: 2024-05-18 DOI: 10.1007/s11864-024-01209-0

Jia Yan, Bo Wang, Guolong Zhang, Caihe Liao, Zijun Zhao, Peiru Wang, Xiuli Wang

{"title":"Neoadjuvant Photodynamic Therapy: An Updated Therapeutic Approach for Non-Melanoma Skin Cancers.","authors":"Jia Yan, Bo Wang, Guolong Zhang, Caihe Liao, Zijun Zhao, Peiru Wang, Xiuli Wang","doi":"10.1007/s11864-024-01209-0","DOIUrl":"10.1007/s11864-024-01209-0","url":null,"abstract":"Opinion statement: Non-melanoma skin cancers (NMSCs) are the most common malignancy and surgical excision is considered treatment of choice for the majority of cases. However, surgery can be very extensive in cases of large, multiple, or cosmetic-sensitive tumors located on areas such as scalp and face or genital region, leading to significant functional and cosmetic deficit. Aminolaevulinic acid photodynamic therapy (ALA-PDT) has emerged as a widely used approach in a variety of skin diseases, demonstrating remarkable efficacy in treatment of actinic keratosis, Bowen disease and basal cell carcinoma. Besides, when employed as a preoperative intervention, ALA-PDT effectively reduces tumor size and minimizes subsequent local surgical morbidity. With its minimally invasive nature and proven effectiveness, ALA-PDT holds significant promise as a neoadjuvant treatment option for NMSCs. In cases where the tumor is large, invasive, multiple, or located in cosmetically and functionally sensitive areas, or when considering patient factors such as age, comorbidity, willingness to undergo surgery, and post-operative quality-of-life, surgical intervention or radiotherapy alone may be impracticable or unacceptable. In such scenarios, neoadjuvant ALA-PDT can offer remarkable outcomes. In order to further ensure the maximum benefit of patients from neoadjuvant PDT, collaboration with multidisciplinary teams and whole-process management may be in need.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"813-826"},"PeriodicalIF":3.8,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome. 低风险骨髓增生异常综合症患者的贫血治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-06-01 Epub Date: 2024-05-30 DOI: 10.1007/s11864-024-01217-0

Muriel R Battaglia, Joseph Cannova, Rafael Madero-Marroquin, Anand A Patel

{"title":"Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.","authors":"Muriel R Battaglia, Joseph Cannova, Rafael Madero-Marroquin, Anand A Patel","doi":"10.1007/s11864-024-01217-0","DOIUrl":"10.1007/s11864-024-01217-0","url":null,"abstract":"Opinion statement: A majority of patients with lower-risk myelodysplastic syndrome (MDS) will present with or develop anemia. Anemia in MDS is associated with decreased quality of life and may correlate with decreased progression-free survival and overall survival. In this state of the art review we summarize current risk stratification approaches to identify lower-risk MDS (LR-MDS), the natural history of the disease, and meaningful clinical endpoints. The treatment landscape of LR-MDS with anemia is also rapidly evolving; we review the role of supportive care, erythropoietin stimulating agents, lenalidomide, luspatercept, hypomethylating agents (HMAs), and immunosuppressive therapy (IST) in the management of LR-MDS with anemia. In patients with deletion 5q (del5q) syndrome lenalidomide has both efficacy and durability of response. For patients without del5q who need treatment, the management approach is impacted by serum erythropoietin (EPO) level, SF3B1 mutation status, and ring sideroblast status. Given the data from the Phase III COMMANDS trial, we utilize luspatercept in those with SF3B1 mutation or ring sideroblasts that have an EPO level < 500 U/L; in patients without an SF3B1 mutation or ring sideroblasts there is equipoise between luspatercept and use of an erythropoietin stimulating agent (ESA). For patients who have an EPO level ≥ 500 U/L or have been previously treated there is not a clear standard of care. For those without previous luspatercept exposure it can be considered particularly if there is an SF3B1 mutation or the presence of ring sideroblasts. Other options include HMAs or IST; the Phase III IMERGE trial supports the efficacy of the telomerase inhibitor imetelstat in this setting and this may become a standard option in the future as well.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"752-768"},"PeriodicalIF":3.8,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors FLT3-ITD阳性急性髓性白血病中新出现的DNA甲基组靶点：与临床批准的 FLT3 抑制剂联合治疗

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-05-02 DOI: 10.1007/s11864-024-01202-7

Melisa Tecik, Aysun Adan

{"title":"Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors","authors":"Melisa Tecik, Aysun Adan","doi":"10.1007/s11864-024-01202-7","DOIUrl":"https://doi.org/10.1007/s11864-024-01202-7","url":null,"abstract":"The internal tandem duplication (ITD) mutation of the FMS-like receptor tyrosine kinase 3 (FLT3-ITD) is the most common mutation observed in approximately 30% of acute myeloid leukemia (AML) patients. It represents poor prognosis due to continuous activation of downstream growth-promoting signaling pathways such as STAT5 and PI3K/AKT. Hence, FLT3 is considered an attractive druggable target; selective small FLT3 inhibitors (FLT3Is), such as midostaurin and quizartinib, have been clinically approved. However, patients possess generally poor remission rates and acquired resistance when FLT3I used alone. Various factors in patients could cause these adverse effects including altered epigenetic regulation, causing mainly abnormal gene expression patterns. Epigenetic modifications are required for hematopoietic stem cell (HSC) self-renewal and differentiation; however, critical driver mutations have been identified in genes controlling DNA methylation (such as DNMT3A, TET2, IDH1/2). These regulators cause leukemia pathogenesis and affect disease diagnosis and prognosis when they co-occur with FLT3-ITD mutation. Therefore, understanding the role of different epigenetic alterations in FLT3-ITD AML pathogenesis and how they modulate FLT3I’s activity is important to rationalize combinational treatment approaches including FLT3Is and modulators of methylation regulators or pathways. Data from ongoing pre-clinical and clinical studies will further precisely define the potential use of epigenetic therapy together with FLT3Is especially after characterized patients’ mutational status in terms of FLT3 and DNA methlome regulators.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"38 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140832375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-Radiotherapy Dysphagia in Head and Neck Cancer: Current Management by Speech-Language Pathologists 头颈部癌症放疗后吞咽困难：言语病理学家的当前处理方法

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-05-01 DOI: 10.1007/s11864-024-01198-0

Roganie Govender, Nicky Gilbody, Gavriella Simson, Rhiannon Haag, Ceri Robertson, Emma Stuart

{"title":"Post-Radiotherapy Dysphagia in Head and Neck Cancer: Current Management by Speech-Language Pathologists","authors":"Roganie Govender, Nicky Gilbody, Gavriella Simson, Rhiannon Haag, Ceri Robertson, Emma Stuart","doi":"10.1007/s11864-024-01198-0","DOIUrl":"https://doi.org/10.1007/s11864-024-01198-0","url":null,"abstract":"Dysphagia, difficulty in eating and drinking, remains the most common side effect of radiotherapy treatment for head and neck cancer (HNC) with devastating consequences for function and quality of life (QOL). Over the past decade, 5-year survival has improved due to multiple factors including treatment advances, reduction in smoking, introduction of the human papillomavirus (HPV) vaccine and more favourable prognosis of HPV-related cancers. Increased prevalence of HPV-positive disease, which tends to affect younger individuals, has led to an elevated number of people living for longer with the sequelae of cancer and its treatment. Symptoms are compounded by late effects of radiotherapy which may lead to worsening of dysphagia for some long-term survivors or new-onset dysphagia for others. Speech-language pathology (SLP) input remains core to the assessment and management of dysphagia following HNC treatment. In this article, we present current SLP management of dysphagia post-radiotherapy. We discuss conventional treatment approaches, the emergence of therapy adjuncts and current service delivery models. The impact of adherence on therapy outcomes is highlighted. Despite treatment advancements, patients continue to present with dysphagia which is resistant to existing intervention approaches. There is wide variation in treatment programmes, with a paucity of evidence to support optimal type, timing and intensity of treatment. We discuss the need for further research, including exploration of the impact of radiotherapy on the central nervous system (CNS), the link between sarcopenia and radiotherapy-induced dysphagia and the benefits of visual biofeedback in rehabilitation.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"3 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140832134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2-Positive Metastatic Colorectal Cancer. HER2 阳性转移性结直肠癌。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-05-01 Epub Date: 2024-03-28 DOI: 10.1007/s11864-024-01183-7

Hannah R Robinson, Wells A Messersmith, Robert W Lentz

{"title":"HER2-Positive Metastatic Colorectal Cancer.","authors":"Hannah R Robinson, Wells A Messersmith, Robert W Lentz","doi":"10.1007/s11864-024-01183-7","DOIUrl":"10.1007/s11864-024-01183-7","url":null,"abstract":"Opinion statement: Targeted treatment strategies are available for human epidermal growth factor receptor 2 (HER2)-positive (amplified and/or overexpressed) metastatic colorectal cancer (mCRC), and HER2 testing is indicated in patients with mCRC. At present, standard of care first-line treatment for those with HER2-positive mCRC remains chemotherapy in combination with epidermal growth factor receptor (EGFR) inhibitors or bevacizumab, depending on RAS/BRAF mutational status and tumor sidedness. HER2-targeted agents should be considered for those with RAS/BRAF wild-type disease in subsequent-line treatment and in first-line treatment for patients not appropriate for intensive therapy. While the choice of anti-HER2 therapy is empiric given lack of head-to-head comparisons, the combination of trastuzumab plus tucatinib has received FDA accelerated approval for use in this setting and is generally the authors' preference. Trastuzumab plus lapatinib, trastuzumab plus pertuzumab, and trastuzumab deruxtecan (T-DXd) also have evidence of efficacy in this setting. As T-DXd has demonstrated activity following treatment with other HER2-targeted regimens and carries an increased risk of high-grade toxicities, the authors favor reserving it for use after progression on prior anti-HER2 therapy. HER2-targeted therapies that inhibit signal transduction appear to have limited activity in those with RAS mutations, including trastuzumab-containing regimens. However, the antibody drug conjugate T-DXd has some data showing efficacy in this setting, and the authors would consider T-DXd in subsequent-line therapy for HER2-positive, RAS-mutated mCRC. Several areas of uncertainty remain regarding how to best utilize HER2-targeted therapies in mCRC. These include the optimal sequence of anti-HER2 therapies with chemotherapy and anti-EGFR therapies, the optimal combination partners for anti-HER2 therapies, and the incorporation of predictive biomarkers to guide use of anti-HER2 therapies. Results of ongoing studies may thus alter the treatment paradigm above in the coming years.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"585-604"},"PeriodicalIF":3.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods 精准心脏病肿瘤学：基于 Omics 的诊断方法的最新进展

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-04-27 DOI: 10.1007/s11864-024-01203-6

Ziyu Kuang, Miao Kong, Ningzhe Yan, Xinyi Ma, Min Wu, Jie Li

引用次数: 0

Photodynamic application in diagnostic procedures and treatment of non-melanoma skin cancers 光动力在非黑素瘤皮肤癌诊断和治疗中的应用

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-04-06 DOI: 10.1007/s11864-024-01193-5

Zhiya Yang, Dongmei Li, Dongmei Shi

引用次数: 0

Role of Metastasis-Directed Therapy in Genitourinary Cancers 转移导向疗法在泌尿生殖系统癌症中的作用

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-04-04 DOI: 10.1007/s11864-024-01199-z

Katie N. Lee, Mai Anh Huynh

{"title":"Role of Metastasis-Directed Therapy in Genitourinary Cancers","authors":"Katie N. Lee, Mai Anh Huynh","doi":"10.1007/s11864-024-01199-z","DOIUrl":"https://doi.org/10.1007/s11864-024-01199-z","url":null,"abstract":"The treatment of oligometastatic genitourinary cancers is a rapidly advancing field with ablative radiotherapy as one of the critical treatment components. The oligometastatic disease state, which can be defined as 1–5 metastatic sites with a controlled primary, represents a distinct clinical state where comprehensive ablative local therapies may provide improved outcomes. Enhanced imaging has increased the number of patients identified with oligometastatic disease. Evidence for improved outcomes with metastasis-directed therapy (MDT) in oligometastatic genitourinary cancers is increasing, and previously published outcome data continues to mature with an increasing body of prospective data to inform the role of MDT in histology-specific settings or in the context of systemic therapy. In select patients, MDT can offer benefits beyond improved local control and allow for time off of systemic therapy, prolonged time until next therapy, or even the hope of cure. However, treatment decisions for locally ablative therapy must be balanced with consideration towards safety. There are exciting advances in technologies to target and adapt treatment in real-time which have expanded options for safer delivery and dose escalation to metastatic targets near critical organs at risk. The role of systemic therapies in conjunction with MDT and incorporation of tumor genetic information to further refine prognostication and treatment decision-making in the oligometastatic setting is actively being investigated. These developments highlight the evolving field of treatment of oligometastatic disease. Future prospective studies combining MDT with enhanced imaging and integrating MDT with evolving systemic therapies will enable the optimal selection of patients most likely to benefit from this “all-or-none” approach and reveal settings in which a combination of therapies could result in synergistic outcomes.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"20 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140584840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ovarian Suppression: Early Menopause and Late Effects. 卵巢抑制：更年期早期和晚期影响。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-04-01 Epub Date: 2024-03-13 DOI: 10.1007/s11864-024-01190-8

Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Roberto Borea, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Cynthia Villarreal-Garza, Jyoti Bajpai, Hee Jeong Kim, Silvia Puglisi, Evandro de Azambuja, Matteo Lambertini

{"title":"Ovarian Suppression: Early Menopause and Late Effects.","authors":"Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Roberto Borea, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Cynthia Villarreal-Garza, Jyoti Bajpai, Hee Jeong Kim, Silvia Puglisi, Evandro de Azambuja, Matteo Lambertini","doi":"10.1007/s11864-024-01190-8","DOIUrl":"10.1007/s11864-024-01190-8","url":null,"abstract":"Opinion statement: Around 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient's comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen. Moreover, it can be used during chemotherapy as a standard strategy for ovarian function preservation in all breast cancer subtypes. In the metastatic setting, ovarian function suppression should be used in all premenopausal patients with hormone receptor-positive breast cancer to achieve a post-menopausal status. Despite its efficacy, ovarian function suppression may lead to several side effects that can have a major negative impact on patients' quality of life if not properly managed (e.g. hot flashes, depression, cognitive impairment, osteoporosis, sexual dysfunction, weight gain). A deep knowledge of the side effects of ovarian function suppression is necessary for clinicians. A correct counselling in this regard and proactive management should be considered a fundamental part of survivorship care to improve treatment adherence and patients' quality of life.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"523-542"},"PeriodicalIF":3.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10997548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer? 谁应该接受晚期胃食管癌免疫疗法？

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-04-01 Epub Date: 2024-02-19 DOI: 10.1007/s11864-024-01189-1

Suhaib Khateeb, Ludimila Cavalcante, Noor Alnairat, Meghana Singh, Ibrahim Halil Sahin, Azhar Saeed, Anwaar Saeed

引用次数: 0